Xencor

Publications

• Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, and Byrd JC (2010).
  CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody. Blood 115(6): 1204-1213.
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, and Desjarlais JR (2010).
  Enhanced antibody half-life improves in vivo activity. Nat Biotechnol, Jan 17, epub ahead of print.
• Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, and Lazar GA (2010)
  Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions. J Mol Bio, Jan 4, epub ahead of print.
• Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE (2009)
  The impact of Fc engineering on an anti-CD19 antibody: increased Fc gamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113:3735-3743
• Holly M. Horton, Matthew J. Bernett, Erik Pong, Matthias Peipp, Sher Karki, Seung Y. Chu, John O. Richards, Igor Vostiar, Patrick F. Joyce, Roland Repp, John R. Desjarlais, and Eugene A. Zhukovsky (2008)
  Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19. Cancer Research 68(19):8049-8057.
• Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, Joyce PF, Szymkowski DE, Desjarlais JR (2008)
  Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Molecular Immunology 45(15):3926-33.
• John O. Richards, Sher Karki, Greg A. Lazar, Hsing Chen, Wei Dang, and John R. Desjarlais (2008)
  Optimization of antibody binding to FcgRIIa enhances macrophage phagocytosis of tumor cells. Molecular Cancer Therapeutics 7: 2517-2527.
• Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY (2007)
  Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discovery Today 12(21-22): 898-910.
• Zhu M.M., Mollet M., and Hubert R.S. (2007)
  Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification. Industrial Chemistry and Biotechnology, Edited by Kent and Riegel, 11th Edition, Chapter 32, p1421-1448, Springer Press, The Netherlands.
• Jonathan Zalevsky, Thomas Secher, Sergei A. Ezhevsky, Laure Janot, Paul M. Steed, Christopher O'Brien, Araz Eivazi, James Kung, Duc-Hanh T. Nguyen, Stephen K. Doberstein, Francois Erard, Bernhard Ryffel, and David E. Szymkowski (2007)
  Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection. The Journal of Immunology 179, 1872-1883.
• Lazar G.A., Desjarlais J.R., Jacinto J., Karki S., and Hammond P.W. (2007)
  A molecular immunology approach to antibody humanization and functional optimization. Molecular Immunology 44, 1986-1998.
• Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Vielmetter J., Carmichael D.F., Hayes R.J., and Dahiyat, B.I. (2006)
  Engineered Antibody Fc Variants with Enhanced Effector Function. Proc Natl Acad Sci USA 103(11), 4005-4010.
• Barbosa, M.D.F.S., Vielmetter, J., Seung, C., Smith, D.D., and Jacinto, J. (2006)
  Clinical link between MHC class II haplotype and interferon-beta (IFN-B) immunogenicity. Clinical Immunology, 118, 42-50
• Szymkowski D.E. (2005)
  Creating the next generation of protein therapeutics through rational drug design. Current Opinion in Drug Discovery & Development 8(5), 590-600
• Vielmetter J. et al. (2005)
  Data management solutions for protein therapeutic research and development, Drug Discovery Today: Biosilico, 10(15), 1065-1071
• Szymkowski D.E. (2005)
  Timely lessons for target-based discovery of anti-inflammatory drugs. Drug Discovery Today, 109(1), 14-17
• Szymkowski D.E. (2004)
  Rational optimization of proteins as drugs: A new era of 'medicinal biology'. Drug Discovery Today, 9(9), 381-383
• Zhukovsky E.A. and Morse R.J. (2004)
  Pleiotropy: the BAFFling truth of the TNF superfamily. Drug Discovery Today: Targets, vol.3, No. 6, pp. 225-227
• Chirino A. J. and Mire-Sluis A. (2004)
  Characterizing biological products and assessing comparability following manufacturing changes. Nature Biotechnology, 22(11), 1383-91
• Zhukovsky E.A., Lee J.O., Villegas M., Chan C., Chu S., Mroske C. (2004)
  TNF ligands: is TALL-1 a trimer or a virus-like cluster? Nature, 427(6973), 413-4
• Chirino, A.J., Ary, M.L., Marshall, S.A. (2004)
  Minimizing the immunogenicity of protein therapeutics. Drug Discovery Today, 9(2), 82-90
• Steed, P.M. et al. (2003)
  Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants. Science, 301, 1895-1898(Full Text)
• Lazar, G.A., Marshall, S.A., Plecs, J.J., Mayo, S.L., Desjarlais, J.R. (2003)
  Designing proteins for therapeutic applications. Curr Opin Struct Biol, 13(4), 513-8
• Szymkowski D.E. (2003)
  Chemical genomics versus orthodox drug development. Drug Discovery Today, 8(4), 157-159
• Marshall, S.A., Lazar, G.A., Chirino, A.J., Desjarlais, J.R., (2003)
  Rational design and engineering of therapeutic proteins. Drug Discovery Today, 8(5), 212-2
• Filikov, A.V., Hayes, R.J., Luo, P., Stark, D.M., Chan, C., Kundu, A., and Dahiyat, B.I. (2002)
  Computational stabilization of human growth hormone. Protein Science, 11, 1452
• Hayes, R.J., Bentzien, J., Ary, M.L., Hwang, M.Y., Jacinto, J.M., Vielmetter, J., Kundu, A., and Dahiyat, B.I. (2002)
  Combining computational and experimental screening for rapid optimization of protein properties. Proc Natl Acad Sci USA, 99, 15926
• Luo, P, Hayes, R.J., Chan, C., Stark, D.M., Hwang, M.Y., Jacinto, J. M., Juvvadi, P., Chung, H.S., Kundu, A., Ary, M.L., and Dahiyat, B.I. (2002)
  Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening. Protein Science, 11(5), 1218
• Dahiyat, B. I., (1999)
  In silico design for protein stabilization. Curr. Op. Biotechnol., 10, 387
• Malakauskas, S. M., and Mayo, S. L., (1998)
  Design, structure and stability of a hyperthermophilic protein variant. Nature Struc. Biol., 5, 470
• Dahiyat, B. I., and Mayo, S. L., (1997)
  Probing the role of packing specificity in protein design. Proc Natl Acad Sci U S A, 94, 10172
• Dahiyat, B., Gordon, D., and Mayo, S. L. (1997)
  Automated design of the surface of protein helices. Protein Sci., 6, 1333
• Dahiyat, B. I., and Mayo, S. L., (1997)
  De novo protein design: fully automated sequence selection. Science, 278, 82
• Dahiyat, B. I., and Mayo, S. L., (1996)
  Protein design automation. Protein Sci., 5, 895